LT3697784T - Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui - Google Patents

Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui

Info

Publication number
LT3697784T
LT3697784T LTEPPCT/EP2018/077677T LTEP2018077677T LT3697784T LT 3697784 T LT3697784 T LT 3697784T LT EP2018077677 T LTEP2018077677 T LT EP2018077677T LT 3697784 T LT3697784 T LT 3697784T
Authority
LT
Lithuania
Prior art keywords
imidazo
treatment
pharmaceutical compositions
inflammatory disorders
pyridine compounds
Prior art date
Application number
LTEPPCT/EP2018/077677T
Other languages
English (en)
Inventor
Steven VAN DER PLAS
Oscar MAMMOLITI
Sébastien MARTINA
Pieter CLAES
Ghjuvanni COTI
Denis ANNOOT
Miriam LÓPEZ RAMOS
René GALIEN
David Amantini
Reginald Brys
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of LT3697784T publication Critical patent/LT3697784T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEPPCT/EP2018/077677T 2017-10-20 2018-10-11 Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui LT3697784T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2018/077677 WO2019076716A1 (en) 2017-10-20 2018-10-11 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Publications (1)

Publication Number Publication Date
LT3697784T true LT3697784T (lt) 2023-10-25

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/077677T LT3697784T (lt) 2017-10-20 2018-10-11 Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui

Country Status (30)

Country Link
US (2) US11564923B2 (lt)
EP (2) EP4265254A3 (lt)
JP (2) JP7292271B2 (lt)
KR (1) KR102757425B1 (lt)
CN (2) CN117534670A (lt)
AR (1) AR113784A1 (lt)
AU (2) AU2018350592B2 (lt)
CA (1) CA3079449A1 (lt)
CO (1) CO2020005200A2 (lt)
DK (1) DK3697784T5 (lt)
ES (1) ES2967432T3 (lt)
FI (1) FI3697784T5 (lt)
GB (1) GB201717260D0 (lt)
HR (1) HRP20231315T1 (lt)
HU (1) HUE063998T2 (lt)
IL (2) IL302615B2 (lt)
LT (1) LT3697784T (lt)
MA (1) MA50391B1 (lt)
MX (1) MX2020003863A (lt)
MY (1) MY205443A (lt)
PH (1) PH12020550230A1 (lt)
PL (1) PL3697784T3 (lt)
PT (1) PT3697784T (lt)
RS (1) RS64800B1 (lt)
SG (1) SG11202003516TA (lt)
SI (1) SI3697784T1 (lt)
SM (1) SMT202300377T1 (lt)
TW (2) TWI805629B (lt)
WO (1) WO2019076716A1 (lt)
ZA (1) ZA202002166B (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
CA3141571A1 (en) 2019-05-28 2020-12-03 Mankind Pharma Ltd. 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
US12600721B2 (en) 2021-02-19 2026-04-14 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
JP2024524631A (ja) 2021-07-12 2024-07-05 ガラパゴス・ナムローゼ・フェンノートシャップ 炎症性疾患の治療
EP4448514A4 (en) 2021-12-16 2025-10-29 Lynk Pharmaceuticals Co Ltd TYK2 INHIBITORS AND ASSOCIATED COMPOSITIONS AND PROCESSES
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161327A1 (en) * 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
JP2024082106A (ja) * 2022-12-07 2024-06-19 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
WO2024153617A1 (en) 2023-01-18 2024-07-25 Galapagos Nv Pharmaceutical compositions and solid forms of compound 1 with fumarate for the treatment of inflammatory disorders
AU2024209905A1 (en) 2023-01-19 2025-09-04 Galapagos Nv Imidazo[4,5-b]pyridine derivatives useful for the treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases and proliferative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2567552T3 (es) 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (en) 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
HUE063998T2 (hu) 2024-02-28
KR102757425B1 (ko) 2025-01-20
US20210169879A1 (en) 2021-06-10
AU2023201522B2 (en) 2024-11-28
JP7292271B2 (ja) 2023-06-16
AU2018350592B2 (en) 2022-12-22
FI3697784T5 (fi) 2024-01-12
DK3697784T3 (da) 2023-10-30
CN111225916A (zh) 2020-06-02
TW202411229A (zh) 2024-03-16
IL302615A (en) 2023-07-01
SI3697784T1 (sl) 2023-11-30
JP2023113834A (ja) 2023-08-16
KR20200074178A (ko) 2020-06-24
IL273943B2 (en) 2023-10-01
CO2020005200A2 (es) 2020-05-29
BR112020007541A2 (pt) 2020-09-24
PH12020550230A1 (en) 2021-02-08
RU2020116376A (ru) 2021-11-22
MY205443A (en) 2024-10-22
IL273943A (en) 2020-05-31
FI3697784T3 (fi) 2023-10-31
RU2020116376A3 (lt) 2021-11-22
AU2018350592A1 (en) 2020-06-04
MX2020003863A (es) 2020-08-13
HRP20231315T1 (hr) 2024-02-16
TWI805629B (zh) 2023-06-21
CN117534670A (zh) 2024-02-09
EP3697784A1 (en) 2020-08-26
AR113784A1 (es) 2020-06-10
GB201717260D0 (en) 2017-12-06
SMT202300377T1 (it) 2024-01-10
AU2023201522A1 (en) 2023-04-13
EP3697784B1 (en) 2023-10-04
IL302615B1 (en) 2024-06-01
JP2020537672A (ja) 2020-12-24
PL3697784T3 (pl) 2024-03-11
TWI866258B (zh) 2024-12-11
US20230310433A1 (en) 2023-10-05
ES2967432T3 (es) 2024-04-30
JP7654031B2 (ja) 2025-03-31
ZA202002166B (en) 2021-05-26
EP4265254A3 (en) 2024-03-13
WO2019076716A1 (en) 2019-04-25
DK3697784T5 (da) 2024-01-15
MA50391A (fr) 2021-04-21
IL302615B2 (en) 2024-10-01
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
EP4265254A2 (en) 2023-10-25
MA50391B1 (fr) 2023-11-30
US11564923B2 (en) 2023-01-31
CA3079449A1 (en) 2019-04-25
RS64800B1 (sr) 2023-11-30
CN111225916B (zh) 2023-11-03
PT3697784T (pt) 2024-01-09
SG11202003516TA (en) 2020-05-28
TW201918483A (zh) 2019-05-16
US12472181B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
LT3697784T (lt) Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui
PL3873900T3 (pl) Imidazo[1,2-a]pirydynowe pochodne jako inhibitory integryny alpha4beta7 do leczenia chorób zapalnych
DK3838274T3 (da) Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-derivat til brug til behandling af cns-lidelser
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
MX389958B (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
EP3250572A4 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
HUE051448T2 (hu) Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
DK3500571T3 (da) Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf
EP3452455A4 (en) SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
IL246823A0 (en) History of benzimidazole and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
HUE052187T2 (hu) Helyettesített pirido[3,4-b]indolok porcrendellenességek kezelésére
LT3737684T (lt) 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ono dariniai ir susiję junginiai, kaip c5a receptoriaus moduliatoriai, skirti vaskulito ir uždegiminių ligų gydymui
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
PL3723807T3 (pl) Leczenie skojarzone obejmujące podawanie 1h-pirazolo­[4,3-b]pirydyn
IL243739A0 (en) History of 1h-pyrazolo[4,3-b]pyridine and their pharmaceutical preparations for the treatment of proliferative disorders
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
HK40014675A (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702604D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3261630A4 (en) Compositions and combinations for the treatment of angiogenesis diseases and disorders
TH1601002629A (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท